The Molbio Diagnostics IPO share allotment takes place today, August 13, following a massive subscription of over 70 times. While grey market sentiment suggests a potential premium, investors should remember that unofficial grey market numbers do not guarantee actual listing performance.
Investors who applied for the Molbio Diagnostics Initial Public Offering (IPO) will see the final outcome of their bids today, August 13, 2026. The company is set to finalize the share allotment process following a strong response from the market. The issue was heavily oversubscribed, recording a total subscription of 70.26 times by the time it closed on August 12.
Checking Your Allotment Status
Applicants can check their allotment status through two primary channels. The official registrar for the issue, Kfin Technologies, provides an online portal where investors can enter their PAN, application number, or DP ID and Client ID to see if they have been allocated shares. Alternatively, investors can visit the official websites of the BSE or NSE to check their status using their application number or PAN. For those who do not receive an allotment, the process for refunding the application money will begin shortly after the allotment is finalized.
Understanding Market Expectations and GMP
The strong demand for the IPO was driven largely by Qualified Institutional Buyers (QIBs), whose portion was subscribed 186.39 times. The Non-Institutional Investor (NII) segment saw a subscription of 49.80 times, while the retail category was subscribed 12.96 times. Following this trend, the Grey Market Premium (GMP) for the stock is currently hovering around Rs 154 per share. Based on the upper price band of Rs 807, this unofficial premium suggests a potential listing gain of approximately 19 percent.
It is essential for investors to understand that GMP is an unofficial, unregulated indicator of market sentiment. It is not an official forecast and does not guarantee the actual price at which the stock will trade when it lists on the exchanges. Listing day volatility is common, and the actual performance can differ significantly from these unofficial estimates.
Business Context and Risks
Molbio Diagnostics operates in the diagnostics sector, primarily focused on its proprietary 'Truenat' technology platform. While the high subscription numbers reflect significant interest, they are not a predictor of long-term financial success. The company’s growth remains tied to its ability to maintain its market share in the point-of-care diagnostics space and adapt to evolving healthcare regulations. The sector is highly competitive, and the company faces constant pressure to innovate and maintain its pricing power.
Investors should view the IPO as a long-term business proposition rather than just a listing-day event. The next major update for shareholders will be the listing of the shares on the BSE and NSE, which is scheduled for August 17, 2026. Once listed, the stock price will be determined by real-time market demand and supply rather than pre-listing sentiment.